Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Can we measure long-term treatment effects in multiple sclerosis?
Evaluation of brainstem involvement in multiple sclerosis.
Virus-induced CD8+ T cells accelerate the onset of experimental autoimmune encephalomyelitis: Implications for how viral infections might trigger multiple sclerosis exacerbations.
Matrine suppresses expression of adhesion molecules and chemokines as a mechanism underlying its therapeutic effect in CNS autoimmunity.
Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination.
Recent imaging advances in neurology.
Brain activity changes in cognitive networks in relapsing-remitting multiple sclerosis - insights from a longitudinal FMRI study.
[Current state of research on multiple sclerosis].
Role of a novel HLA-DQA1*01:02;DRB1*15:01 mixed-isotype heterodimer in the pathogenesis of 'humanized' multiple sclerosis-like disease.
Dopamine favors expansion of glucocorticoid-resistant IL-17-producing T cells in multiple sclerosis.
CD21 positive B cell: A novel target for treatment of multiple sclerosis.
Six-year follow-up of a case series with non-communicating syringomyelia in multiple sclerosis.
Carbon Nanotube-Bilirubin Oxidase Bioconjugate as a New Biofuel Cell Label for Self-Powered Immunosensor.
The Parallel Analysis of Phase Sensitive Inversion Recovery (PSIR) and Double Inversion Recovery (DIR) Images Significantly Improves the Detection of Cortical Lesions in Multiple Sclerosis (MS) since Clinical Onset.
Tolerogenic dendritic cells produced by Lentiviral-mediated CD40- and IL-23p19-specific shRNA can ameliorate experimental autoimmune encephalomyelitis by suppressing Th17 cells.
Estrogen receptor β ligand therapy activates PI3K/Akt/mTOR signaling in oligodendrocytes and promotes remyelination in a mouse model of multiple sclerosis.
The Bioenergetic Health Index: a new concept in mitochondrial translational research.
Clinical data and regulatory issues of biosimilar products.
Atypical Optic Neuritis.
Lymphomatosis cerebri Presenting as a Recurrent Leukoencephalopathy.
IL-12, but not IL-23, induces the expression of IL-7 in microglia and macrophages: Implications for multiple sclerosis.
[Multiple sclerosis, neuromyelitis optica and spasticity: control of specific symptoms and quality of life].
Carbon Monoxide and the Brain : Time to Rethink the Dogma.
Genetic predictors of relapse rate in pediatric MS.
Depression as a predictor of occupational transition in a multiple sclerosis cohort.
Pages
« first
‹ previous
…
343
344
345
346
347
348
349
350
351
…
next ›
last »